frontiers | Frontiers in Immunology

TYPE Correction
PUBLISHED 20 June 2024
DOI 10.3389/fimmu.2024.1441999

OPEN ACCESS

EDITED AND REVIEWED BY
Michael Dougan,
Massachusetts General Hospital and Harvard Medical School, United States

*CORRESPONDENCE
Mark A. Kroenke
mkroenke@amgen.com

†PRESENT ADDRESS
Christina L. Zuch de Zafra,
Nonclinical Sciences, Seagen, South San Francisco, CA, United States
Michael Archer,
Drug Safety and Pharmacovigilance, Atara Biotherapeutics, Thousand Oaks, CA, United States
Gurleen Saini,
Immunogenicity Characterization, Boehringer Ingelheim, Ridgefield, CT, United States

RECEIVED 01 June 2024
ACCEPTED 13 June 2024
PUBLISHED 20 June 2024

CITATION
Kroenke MA, Manning MS, Zuch de Zafra CL, Zhang X, Cook KD, Archer M, Lolkema MP, Wang J, Hoofring S, Saini G, Aeffner F, Ahern E, Cabanas EG, Govindan R, Hui M, Gupta S and Mytych DT (2024) Corrigendum: Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein. *Front. Immunol.* 15:1441999. doi: 10.3389/fimmu.2024.1441999

Corrigendum: Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein

Mark A. Kroenke[1]*, Marta Starcevic Manning[2], Christina L. Zuch de Zafra[3†], Xinwen Zhang[4], Kevin D. Cook[5], Michael Archer[6†], Martijn P. Lolkema[7], Jin Wang[2], Sarah Hoofring[2], Gurleen Saini[2†], Famke Aeffner[3], Elizabeth Ahern[8], Elena Garralda Cabanas[9], Ramaswamy Govindan[10], Mun Hui[11], Shalini Gupta[2] and Daniel T. Mytych[1]

[1]Clinical Immunology, Amgen, Thousand Oaks, CA, United States, [2]Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States, [3]Translational Safety & Bioanalytical Sciences, Amgen, South San Francisco, CA, United States, [4]Clinical Pharmacology, Modeling, and Simulation, Amgen, South San Francisco, CA, United States, [5]Pharmacokinetics and Drug Metabolism, Amgen, South San Francisco, CA, United States, [6]Global Safety, Amgen, Thousand Oaks, CA, United States, [7]Early Development, Amgen, Thousand Oaks, CA, United States, [8]Medical Oncology, Monash Health, Clayton, VIC, Australia, [9]Research Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain, [10]Division of Hematology and Oncology, Washington University Medical School, St. Louis, MO, United States, [11]Chris O'Brien Lifehouse, Camperdown, NSW, Australia

KEYWORDS

PD-1, IL-21, immunogenicity, anti-drug antibodies, mutein, IgE

A Corrigendum on

Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein

By Kroenke MA, Starcevic Manning M, Zuch de Zafra CL, Zhang X, Cook KD, Archer M, Lolkema MP, Wang J, Hoofring S, Saini G, Aeffner F, Ahern E, Cabanas EG, Govindan R, Hui M, Gupta S and Mytych DT (2024). *Front. Immunol.* 15:1345473. doi: 10.3389/fimmu.2024.1345473

Error in Figure/Table

In the published article, there was an error in Figure 2A as published. The Figure 2A y-axis should read "Serum concentration (ng/mL)". The corrected Figure 2 is attached.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

10.3389/fimmu.2024.1441999

Publisher's note



FIGURE 2
IL-21 mutein domain enhanced the antibody response to 22D4 in cynomolgus monkeys. Cynomolgus monkeys were dosed with 5 mg/kg AMG 256, 5 mg/kg 22D4, or 5 mg/kg 22D4 plus 0.1 mg/kg recombinant human IL-21. **(A)** AMG 256 or 22D4 serum levels were measured over time in each of the 3 treatment groups. **(B)** The ADA response in each dosing group was assessed on day 15 and day 25 by UNISA. **(C)** Domain characterization was performed on AMG 256 dosed animals at the day 25 time point. Serum samples were pre-treated with either AMG 256 or 22D4 and re-tested in the antibody assay. Percent depletion indicates the signal change from the pre-treated sample relative to the untreated sample.